Raphas Co Ltd
Raphas has a debt-to-equity ratio of 1.28, indicating a leveraged capital structure, and a current ratio of 0.86, suggesting potential short-term liquidity constraints. The company's cash and equivalents amount to 1.33 billion KRW, while its long-term debt stands at 36.27 billion KRW, resulting in a negative net cash position after subtracting total debt. Free cash flow is negative at -1.77 billion KRW, and operating cash flow is 1.43 billion KRW, highlighting a mismatch between operating performance and capital outflows. Profitability metrics are weak, with a return on equity of -15.23% and a return on assets of -5.75%, both significantly below the industry median for Personal Products. The company reported a net loss of 4.31 billion KRW and an operating loss of 3.58 billion KRW, indicating a challenging operating environment. The company's revenue is concentrated in its domestic and overseas markets, with no disclosed segment breakdown. However, the absence of segment-specific data limits the ability to assess geographic or product diversification. The company's exposure to the Personal Products industry is high, with no clear diversification into other sectors. Looking ahead, Raphas is expected to see a revenue increase from 30.99 billion KRW to 409.00 billion KRW, a significant 12.9% year-over-year growth. However, the company's operating and net losses suggest that this growth may not yet be translating into profitability. Historical revenue trends and the current outlook indicate a focus on expanding market reach rather than immediate margin improvement. The company faces medium liquidity risk due to its negative net cash position and low dilution risk, as indicated by the risk assessment. No dilution sources were identified in the latest filings, and the company has not issued new shares recently. However, the negative free cash flow and high debt levels could necessitate future capital raising, which may involve dilution. Recent events include the company's latest financial results, which show a net loss and a significant operating loss. Analysts have raised their revenue estimates, suggesting optimism about the company's future performance. However, the company's earnings per share (EPS) remain negative at -484.00 KRW, indicating ongoing profitability challenges.
Business. Raphas Co Ltd develops and sells microneedle patches using transdermal drug delivery system (TDDS) technology, with products in beauty, over-the-counter (OTC) drug, and prescription drug categories, as well as medical device and health functional food businesses.
Classification. Raphas is classified in the Consumer Non-Cyclicals sector under Personal Products, with a confidence level of 0.92 based on verified market data.
- Raphas has a leveraged capital structure with a debt-to-equity ratio of 1.28 and a negative net cash position.
- The company is unprofitable, with a return on equity of -15.23% and a return on assets of -5.75%.
- Revenue is expected to grow significantly, but this has not yet translated into profitability.
- The company faces medium liquidity risk and low dilution risk based on the risk assessment.
- Analysts are optimistic about future revenue growth, but current earnings remain negative.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.